BELLUS Health Inc. (BLU)
Stock analysis · NASDAQ · Healthcare · Biotechnology
BELLUS Health Inc. (BLU) is a publicly traded company in the Healthcare sector. Latest price: $14.75. Market cap $1.87B. Trailing PE -22.34. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Proprietary Signals
About BELLUS Health Inc.
BELLUS Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, and founded in 1993. The firm focuses on developing therapeutic solutions for refractory chronic cough (RCC) and other related cough hypersensitivity conditions. Its leading product candidate, BLU-5937, an antagonist designed to block the P2X3 receptor, is currently progressing through Phase II clinical trials for the treatment of both RCC and chronic pruritus.
Valuation
| P/E (TTM) | -22.34× |
|---|---|
| P/S (TTM) | 116865.18× |
| P/B | 4.35× |
| P/FCF (TTM) | -19.08× |
| EV / EBITDA | -23.58× |
| EV / Sales | 111492.25× |
| Earnings Yield | -4.47% |
| Free Cash Flow Yield | -5.24% |
Fundamentals
| Enterprise Value | $1.78B |
|---|---|
| Revenue (TTM) | $16.00K |
| Net Income (TTM) | -$83.63M |
| Free Cash Flow (TTM) | -$97.90M |
| Net Debt | -$85.97M |
| Working Capital | $340.02M |
| Gross Margin | -21967104.08% |
| Operating Margin | -486768.75% |
| Net Margin | -475500.00% |
| Return on Equity | -22.28% |
| Return on Invested Capital | -19.85% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap